NanoViricides starts Phase II DRC trial of oral NV-387 gummies in Bundibugyo Ebola patients

By Public Technologies
  • NanoViricides began enrolling and dosing patients in a Phase II trial of NV-387 oral gummies for Ebola in the Democratic Republic of Congo.
  • No results have been presented; the study is designed to generate safety, tolerability, and effectiveness data in a later randomized phase.
  • The initial dose run-in aims to set a tolerable dosing approach for sicker patients before moving into the efficacy evaluation.
  • The program targets Bundibugyo ebolavirus, positioning NV-387 as a potential oral alternative to infusion-based treatments under evaluation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609280845ACCESSWRNAPR_____1227696) on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.